The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1379812
This article is part of the Research Topic Novel Preclinical Model, Biomarker, Treatment and Drug Delivery to Address Immune Evasion in Cancer View all 11 articles
NSCLC immunotherapy response predicted by tumor infiltrating T cells via noninvasive radiomic approach
Provisionally accepted- Zhejiang University, Hangzhou, China
Identifying patients with Non-Small Cell Lung Cancer (NSCLC) who are optimal candidates for immunotherapy is a cornerstone in clinical decision-making. The Tumor Immune Microenvironment (TIME) is intricately linked with both the prognosis of the malignancy and the efficacy of immunotherapeutic interventions. CD8+ T cells, and more specifically, tissue-resident memory CD8+ T cells (CD8+ TRM cells), are postulated to be pivotal in orchestrating the immune system's assault on tumor cells. Nevertheless, the accurate quantification of immune cell infiltration-and by extension, the prediction of immunotherapeutic efficacy-remains a significant scientific frontier. In this study, we introduce a cutting-edge noninvasive radiomic model, grounded on TIME markers (CD3+ T, CD8+ T, and CD8+ TRM cells), to infer the levels of immune cell infiltration in NSCLC patients receiving immune checkpoint inhibitors (ICIs), and ultimately, to predict their response to immunotherapy. Our empirical evidence reveals that patients with substantial CD8+ T cell infiltration experience markedly improved Progress Free Survival (PFS) compared to those with minimal infiltration, asserting the status of the CD8+ T cell as an independent prognosticator of PFS in the context of immunotherapy. Although CD8+ TRM cells demonstrated the greatest predictive accuracy for immunotherapy response, their predictive strength for PFS was marginally surpassed by that of CD8+ T cells. These insights advocate for the application of the proposed noninvasive radiomic model, which utilizes TIME analysis, as a reliable predictor for immunotherapy outcomes and PFS in NSCLC patients.
Keywords: Non-small cell lung cancer, Tumor immune microenvironment, immune checkpoint inhibitors, Immunotherapy, Radiomic
Received: 31 Jan 2024; Accepted: 12 Aug 2024.
Copyright: © 2024 Chai, Min, Dong, Chen, Li, Wu, Tan, Yang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ying Chai, Zhejiang University, Hangzhou, China
Jie Min, Zhejiang University, Hangzhou, China
Yongyuan Chen, Zhejiang University, Hangzhou, China
Wenshan Li, Zhejiang University, Hangzhou, China
Yimin Wu, Zhejiang University, Hangzhou, China
Yanbin Tan, Zhejiang University, Hangzhou, China
Fan Yang, Zhejiang University, Hangzhou, China
Pin Wu, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.